Clinical Trials Logo

Filter by:
NCT ID: NCT04998188 Recruiting - Knee Osteoarthritis Clinical Trials

Hydrolyzed Collagen Formulation vs Placebo in Knee Osteoarthritis

Start date: February 16, 2022
Phase: N/A
Study type: Interventional

The aim of the study is to compare the 6 months clinical outcome of the treatment with a single intra-articular collagen injection versus a single placebo (saline solution) infiltration in the infiltrative treatment of knee osteoarthritis. The evaluation will be performed through clinical, subjective and objective assessments.

NCT ID: NCT04996875 Recruiting - Clinical trials for Aggressive Systemic Mastocytosis (ASM)

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Start date: November 9, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).

NCT ID: NCT04996017 Recruiting - Clinical trials for Mesotheliomas Pleural

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

AtezoMeso
Start date: December 14, 2021
Phase: Phase 3
Study type: Interventional

This is a multicentric double-blind, placebo controlled, phase III trial. In this study, patients who underwent to a surgical resection of pleural mesothelioma and are without signs of macroscopic residual disease will be randomized 2:1 to receive atezolizumab or placebo. Patients will be treated for 12 months or until recurrence, unacceptable toxicity or patient/physician decision, whichever occurs first. Randomization will be done via a centralized system and patients will be stratified histology (epithelioid vs non epithelioid) and stage (I vs >I). Patients will be radiologically evaluated after surgical procedure before starting therapy and then every 12 weeks for 24 months or until disease progression. At screening patients should be without macroscopic residual disease. Quality of life questionnaire will be administered to patient at baseline and every 12 weeks. During the study baseline tumor blocks will be centrally analyzed to determinate biological characteristics and gene expression.

NCT ID: NCT04995991 Recruiting - Clinical trials for Developmental Dyslexia

Rhythmic Reading Training: Comparing the Rhythmic and Visual Contributions to Reading Improvement

Start date: July 9, 2018
Phase: N/A
Study type: Interventional

The main objective of the study is to evaluate the specific effect of the sub-components of the reading training program Rhythmic Reading Training (RRT) on reading speed and accuracy in a sample of Italian students with developmental dyslexia (DD). More precisely, in order to better understand the neuropsychological mechanisms involved in reading improvements following RRT, the specific contribution of the visual component of the training (presence of a visual cue) will be investigated in a study with between-groups design.

NCT ID: NCT04995640 Recruiting - Aortic Diseases Clinical Trials

CILCA Arch Registry: Management and Outcomes of Open and Endovascular Repair

Start date: October 1, 2021
Phase:
Study type: Observational

This registry aims to provide insights on the pathogenic mechanisms that expose subjects with CILCA arch to the increased risk of postoperative complications. So, the CILCA arch registry will capture clinical data and medical images of subjects with CILCA arch treated by surgical or endovascular (TEVAR) means. Study Design: International Multicenter and Observational registry Estimated Enrolment: 500 patients, with competitive enrolment. Clinical Follow up: Postoperatively at 30 days, at 12 months, and yearly after.

NCT ID: NCT04995627 Recruiting - Gitelman Syndrome Clinical Trials

Salt Supplementation in Gitelman Syndrome

Start date: April 19, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effect of salt (NaCl) supplementation on serum potassium and clinical signs and symptoms in patients with Gitelman syndrome.

NCT ID: NCT04995133 Recruiting - Critically Ill Clinical Trials

Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs.

Start date: July 14, 2021
Phase: Phase 4
Study type: Interventional

Colistin is an antibiotic active against several classes of multi-resistant gram-negative bacteria; the drug should be used in high doses in patients on continuous renal replacement therapy, since the drug is eliminated through the dialysis filter. This is an Open-label, Phase 4, interventional, prospective, single-center pilot study aimed to analyze the concentrations of colistin in plasma and ultrafiltrate by liquid chromatography/mass spectrometry, in 20 critically ill patients admitted to intensive care and suffering from severe infections by multi-resistant bacteria, who receive continuous renal replacement therapy.

NCT ID: NCT04994795 Recruiting - Clinical trials for Non-small Cell Lung Cancer Metastatic

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

DEEP-Lung-IV
Start date: August 21, 2021
Phase:
Study type: Observational

Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.

NCT ID: NCT04994717 Recruiting - Clinical trials for Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

Start date: November 2, 2021
Phase: Phase 3
Study type: Interventional

The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS and (OS) of participants receiving standard of care (SOC) chemotherapy.

NCT ID: NCT04994379 Recruiting - Healthy Clinical Trials

Investigating the Effects of Intensity of Transcranial Direct Current Stimulation on Subjective Appetite

tDCS
Start date: August 1, 2021
Phase: N/A
Study type: Interventional

This is a randomized double-blind sham controlled systematic investigation to understand the importance of the brain region that controls the tongue and the submental muscle region on perceived appetite. The results of this study can have clinical implications for a phenomenon called hyperphagia.